Comparison of breast cancer patients who underwent partial mastectomy (PM) with mini latissimus dorsi flap (MLDF) and subcutaneous mastectomy with implant (M + I) regarding quality of life (QOL), cosmetic outcome and survival rates.
Adult
Aged
Breast
/ pathology
Breast Implants
Breast Neoplasms
/ mortality
Clinical Decision-Making
Disease-Free Survival
Esthetics
Female
Follow-Up Studies
Humans
Mammaplasty
/ instrumentation
Mastectomy, Segmental
/ adverse effects
Mastectomy, Subcutaneous
/ adverse effects
Middle Aged
Patient Satisfaction
Patient Selection
Prognosis
Quality of Life
Retrospective Studies
Superficial Back Muscles
/ transplantation
Surgical Flaps
/ transplantation
Survival Rate
Young Adult
Breast-conserving surgery
Cosmetic evaluation
EORTC-QLO BR23
EORTC-QLO C30
Implant reconstruction; quality of life
Japanese breast cancer society cosmetic evaluation scale
Mini latissimus dorsi flap
Subcutaneous mastectomy
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
05 May 2020
05 May 2020
Historique:
received:
25
01
2020
accepted:
20
04
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
9
2
2021
Statut:
epublish
Résumé
The latissimus dorsi muscle has long been used in breast cancer (BC) patients for reconstruction. This study aimed to compare early stage BC patients who had partial mastectomy (PM) with mini latissimus dorsi flap (MLDF) and subcutaneous mastectomy with implant (MI) with respect to quality of life (QoL), cosmetic outcome (CO), and survival rates. The data of patients who underwent PM + MLDF (Group 1) and M + I (Group 2) between January 2010 and January 2018 were evaluated. Both groups were compared in terms of demographics, clinical and pathological characteristics, surgical morbidity, survival, quality of life, and cosmetic results. The EORTC-QLQ C30 and EORTC-QLO BR23 questionnaires and the Japanese Breast Cancer Society (JBCS) Cosmetic Evaluation Scale were used to assess the quality of life and the cosmetic outcome, respectively. A total of 317 patients were included in the study, 242 (76.3%) of them in group 1 and 75 (23.6%) of them in group 2. Median follow-up time was 56 (14-116) months. There were no differences identified between the groups in terms of tumor histology, hormonal receptors and HER-2 positivity, surgical morbidity, and 5-year overall and disease-free survival. Group 2 patients were significantly younger than group 1 (p = 0.003). The multifocality/multicentricity rate was higher in group 2 (p ≤ 0.001), whereas tumor size (p = 0.009), body mass index (BMI, p = 0.006), histological grade (p ≤ 0.001), lymph node positivity (p = 0.002), axillary lymph node dissection (ALND) rate (p = 0.005), and presence of lympho-vascular invasion (LVI, p = 0.013) were significantly higher in group 1. When the quality of life was assessed by using the EORTC QLQ C30 and BR23 questionnaires, it was seen that the body image perception (p < 0.001) and nausea/vomiting score (p = 0.024) were significantly better in PM + MLDF group whereas physical function score was significantly better in M + I group (p = 0.012). When both groups were examined in terms of cosmesis with JBCS Cosmetic Evaluation Scale, good cosmetic evaluation score was significantly higher in patients in MLDF group (p = 0.01). The results of this study indicate that in comparison to M + I procedure, the PM + MLDF procedure provides significantly superior results in terms of body image and cosmetic result with similar morbidity and oncologic outcomes. In selected patients with small breasts and a high tumor/breast ratio, PM + MLDF may be an alternative to subcutaneous mastectomy and implant.
Identifiants
pubmed: 32370753
doi: 10.1186/s12957-020-01858-z
pii: 10.1186/s12957-020-01858-z
pmc: PMC7201547
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Références
Psychiatr Pol. 2017 Oct 29;51(5):871-888
pubmed: 29289967
Asia Pac J Oncol Nurs. 2014 Apr-Jun;1(1):22-32
pubmed: 27981079
Eur J Surg Oncol. 2015 Mar;41(3):426-32
pubmed: 25578249
J Clin Oncol. 2008 Jul 1;26(19):3248-58
pubmed: 18474876
Ann Surg Oncol. 2014 Mar;21(3):704-16
pubmed: 24515565
Eur J Surg Oncol. 2005 Oct;31(8):817-23
pubmed: 16043322
BJS Open. 2018 May 22;2(4):162-174
pubmed: 30079385
J Plast Reconstr Aesthet Surg. 2018 Jan;71(1):15-20
pubmed: 28918997
Breast Cancer Res Treat. 2014 Jul;146(2):235-44
pubmed: 24928527
Breast Cancer Res Treat. 2009 Feb;113(3):577-83
pubmed: 18330695
J Plast Reconstr Aesthet Surg. 2016 Aug;69(8):1080-6
pubmed: 26975786
Ann Surg Oncol. 2017 Dec;24(13):3896-3902
pubmed: 28916978
PLoS One. 2017 Dec 6;12(12):e0189127
pubmed: 29211792
Eur Rev Med Pharmacol Sci. 2015 Jul;19(13):2477-81
pubmed: 26214785
Br J Surg. 1997 Jan;84(1):101-5
pubmed: 9043470
Eur Rev Med Pharmacol Sci. 2017 Jun;21(11):2572-2585
pubmed: 28678328
Ann Surg Oncol. 2015 Apr;22(4):1118-27
pubmed: 25297900
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Breast Cancer Res Treat. 2019 Jan;173(2):267-274
pubmed: 30361873
Plast Reconstr Surg. 2019 Nov;144(5):931e-932e
pubmed: 31688775
Medicine (Baltimore). 2018 Jun;97(24):e10979
pubmed: 29901587
Semin Plast Surg. 2004 May;18(2):149-55
pubmed: 20574493
Eur J Breast Health. 2019 Jul 01;15(3):141-146
pubmed: 31312788
Aesthetic Plast Surg. 2009 May;33(3):413-20
pubmed: 19340480
Breast. 2002 Feb;11(1):58-65
pubmed: 14965647
Eur J Surg Oncol. 2019 Aug;45(8):1317-1327
pubmed: 30795956
Gland Surg. 2018 Dec;7(6):554-559
pubmed: 30687628
J Am Coll Surg. 2009 Jan;208(1):67-74
pubmed: 19228505
PET Clin. 2018 Jul;13(3):339-354
pubmed: 30100074
Oncologist. 2019 Mar;24(3):313-318
pubmed: 30139836
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Int Surg. 1990 Jul-Sep;75(3):166-70
pubmed: 2242969
Breast J. 2008 Jul-Aug;14(4):340-4
pubmed: 18537916
Gland Surg. 2018 Dec;7(6):506-519
pubmed: 30687624
World J Surg. 2016 Jun;40(6):1362-72
pubmed: 26842691
Mol Clin Oncol. 2016 Oct;5(4):365-371
pubmed: 27699027
J Clin Oncol. 1996 Oct;14(10):2756-68
pubmed: 8874337
Ann Plast Surg. 2017 Jun;78(6S Suppl 5):S282-S285
pubmed: 28296716
BMC Public Health. 2018 Aug 10;18(1):999
pubmed: 30097040
Asian Pac J Cancer Prev. 2011;12(5):1283-7
pubmed: 21875283
Clin Breast Cancer. 2017 Jul;17(4):307-315
pubmed: 28336245
Am J Surg. 2019 Mar;217(3):514-518
pubmed: 30348443
Breast Cancer Res Treat. 2011 Oct;129(3):703-16
pubmed: 21080063
Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):567-73
pubmed: 8226150
Am J Surg. 2019 May;217(5):862-867
pubmed: 30739736
J Plast Reconstr Aesthet Surg. 2017 Sep;70(9):1203-1209
pubmed: 28734752
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Chirurgia (Bucur). 2017 Jan-Feb;112(1):12-17
pubmed: 28266287
Breast Cancer Res Treat. 2009 Sep;117(2):365-70
pubmed: 19082705
Surg Today. 2011 Apr;41(4):477-89
pubmed: 21431479
Rev Assoc Med Bras (1992). 2017 Jul;63(7):583-589
pubmed: 28977083